Our discussions during this presentation will include forward-looking statements. Actual results could differ materially from those projected in the forward-looking statements. The factors that could cause actual results to differ are discussed in Pfizer’s 2010 Annual Report on Form 10-K and in our reports on Form 10-Q and Form 8-K.

These reports are available on our website at www.pfizer.com in the "Investors—SEC Filings" section.
A Strengthened R&D Organization

- Centered on pipeline delivery
- Applying a breadth of science and technology
- Improving decision-making and clinical development of candidates
- Delivering smarter, more authentic integration of science and business
- Establishing a new standard for engagement of world class scientific talent
- Driving a vibrant culture of science
A Comprehensive Turn-Around Strategy is Underway

Focused on Three Horizons to Drive Sustained Progress

**Horizon 1**
- Deliver the Portfolio
- Maximize productivity and ROI
- Deep knowledge of pathogenic mechanisms
- Medically differentiated products

**Horizon 2**
- Innovate New Capabilities
- Next generation therapeutics
- Open and external innovation
- Vaccines for all ages and geographies

**Horizon 3**
- R&D Ecosystem of the Future
- Precision Medicine
- Networked, interactive R&D
- Breakthrough productivity

---

Next generation therapeutics

Open and external innovation

Vaccines for all ages and geographies
Recent Moves to Accelerate Our Progress

1. Creating greater focus to strengthen our scientific core

2. Driving competitive advantage through strategic externalization

3. Positioning ourselves for differentiated innovation

Creating an engine for sustainable innovation

Improving output and reducing costs to drive productivity

- Probability of Success
- Quality of Output
- Speed
- Cost per Product
Today’s Key Registration Assets

...and Potential Key Near-Term Submissions

<table>
<thead>
<tr>
<th>In Registration</th>
<th>Near Term Filing Opportunities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prevenar 13 Adult <em>(Pneumococcal Disease)</em></td>
<td>Apixaban <em>(Atrial Fibrillation)</em></td>
</tr>
<tr>
<td>Pristiq <em>(Vasomotor Symptoms of Menopause)</em></td>
<td>Axitinib <em>(Renal Cell Carcinoma)</em></td>
</tr>
<tr>
<td>✓ Xiapex <em>(Dupuytren's Contracture)</em></td>
<td>Bosutinib <em>(Chronic Myelogenous Leukemia)</em></td>
</tr>
<tr>
<td>Tafamidis meglumine <em>(transthyretin amyloidosis polyneuropathy)</em></td>
<td>Crizotinib <em>(Non-Small Cell Lung Cancer)</em></td>
</tr>
<tr>
<td></td>
<td>Tofacitinib <em>(formerly Tasocitinib, Rheumatoid Arthritis)</em></td>
</tr>
</tbody>
</table>

✅ Xiapex recently approved in the EU

* Crizotinib rolling submission underway in the U.S.
Today’s Rich Phase 3 Portfolio

<table>
<thead>
<tr>
<th>13 NMEs</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bapineuzumab</strong> – Alzheimer’s Disease</td>
</tr>
<tr>
<td><strong>Bazedoxifene-conjugated estrogens (Aprela)</strong> – Menopausal Vasomotor Symptoms</td>
</tr>
<tr>
<td><strong>Axitinib</strong> – Renal Cell Carcinoma</td>
</tr>
<tr>
<td><strong>Crizotinib</strong> – Lung Cancer</td>
</tr>
<tr>
<td><strong>Moxidectin</strong> – River Blindness</td>
</tr>
<tr>
<td><strong>Inotuzumab</strong> – Aggressive Non-Hodgkin’s Lymphoma</td>
</tr>
<tr>
<td><strong>Tofacitinib</strong> – Rheumatoid Arthritis</td>
</tr>
<tr>
<td><strong>Zithromax / chloro</strong> – Malaria</td>
</tr>
<tr>
<td><strong>Tanezumab</strong> – OA Pain (<em>on clinical hold</em>)</td>
</tr>
<tr>
<td><strong>Bosutinib</strong> – Chronic Myelogenous Leukemia</td>
</tr>
<tr>
<td><strong>Neratinib</strong> – Breast Cancer</td>
</tr>
<tr>
<td><strong>PF-299804</strong> – Lung Cancer</td>
</tr>
<tr>
<td><strong>Dimebon</strong> – Alzheimer’s Disease</td>
</tr>
</tbody>
</table>

**Several New Indications**

- **Apixaban** – Atrial Fibrillation
- **Apixaban** – VTE Treatment
- **Tofacitinib** – Psoriasis (Oral)
- **Dimebon** – Huntington’s Disease
- **Xiapex** – Peyronie’s Disease
Early to Mid-Stage Pipeline Shapes the Future

<table>
<thead>
<tr>
<th>Category</th>
<th>Description</th>
</tr>
</thead>
</table>
| Immunology & Inflammation | • Strong pipeline of anti-inflammatory drugs across multiple disease areas  
                         |   – *e.g.*, anti-IL21 receptor, anti-madcam antibody and anti-TNF nanobody                                                               |
| CVMED                   | • Growing diabetes clinical pipeline  
                         |   – *e.g.*, SGLT2 inhibitor, Glucokinase activators and four novel insulin sensitizing mechanisms                                           |
| Oncology                | • Robust oncology pipeline, applying Precision Medicine principles  
                         |   – *e.g.*, PI3K-mTOR inhibitors, VEGF/Ang-2 inhibitor, ALK1 mAb and CDK4/6 inhibitors                                                     |
| Vaccines                | • Expanding pipeline of infectious disease vaccines  
                         |   – *e.g.*, Meningococcal group B for adolescents and *S. aureus* for hospital infections                                                 |
| Neuroscience            | • Growing Neuroscience pipeline across disease areas and target classes  
                         |   – *e.g.*, drugs targeting 5HT6, mAb to Amyloid, PDE10 and α4β2                                                                          |
Next Generation Therapeutics: Inotuzumab

Specific mAb-like target binding allows precise delivery to cancer cells

- Inotuzumab ozogamicin is a potent anti-CD22 antibody-calicheamicin conjugate

- Major B-cell malignancy currently under study:
  - Phase 2 study with Inotuzumab plus Rituximab in refractory Non-Hodgkin’s Lymphoma (NHL) demonstrated positive proof of concept, with strong efficacy and favorable tolerability
  - Phase 3 study started in patients with aggressive NHL tumors

Over 10 pre-clinical Antibody Drug Conjugate (ADC) programs underway; first ADC against cancer stem cells expected to hit FIH within a year
Pfizer’s Open Innovation Model: Centers for Therapeutic Innovation (CTI)

UCSF agreement completed

Progressing discussions with other highly regarded institutions

Agreements signed with:
- NYU Langone Medical Center
- Rockefeller University Hospital
- Memorial Sloan-Kettering Cancer Center
- Mount Sinai Hospital
- Columbia University Medical Center
- Albert Einstein College of Medicine
- Weill Cornell Medical College

NYC – East River Science Park
What is “Precision Medicine”?

Precision Medicine: Right Target, Right Drug(s), Right Patient

Medicines targeting patient segments that will have an optimal response to therapy

Building disease understanding to identify the right pathways and targets

Linking disease understanding and clinical outcomes

Segmented, not personalized (5-20%+ patient subgroups, not individuals)
Precision Medicine Expected to Drive Improved Drug Development and Commercial Advantage

Clinical Development

Bigger Treatment Effect

Smaller Clinical Trials + Less Costly, Faster Trial Completion

Commercial Benefits

Patients Treated More Likely to Benefit

Longer Time on Treatment

Earlier Regulatory Submission + Earlier Launch

More Dramatic Effect in Treated Patients ➔ Value of Treatment Easier to Demonstrate to Payers
Examples of Precision Medicine Approaches by Pfizer

Drug/Target: Crizotinib/Anaplastic Lymphoma Kinase
Targeted Patients: NSCLC patients with EML-4/ALK translocation

Drug/Target: PD-332991 Cyclin-Dependent Kinase 4/6
Targeted Patients: Luminal-B Breast Cancer (Cyclin D amplified, p16+, Rb+)

Drug/Target: RN-316/PCSK9
Targeted Patients: Hypercholesteremic patients unresponsive to statins - many will be FH pts heterozygous for mutant LDLR

Drug/Target: PF-04991532 Liver Glucokinase
Targeted Patients: Type 2 diabetes patients who are contra-indicated for or non-tolerant of metformin

Drug/Target: ATR-107/IL-21R
Targeted Patients: Patients with autoimmunes diseases that over-express IL-21

Drug/Target: Inotuzumab/CD-22
Targeted Patients: CD-22+ Hematological malignancies

Drug/Target: RN-316/PCSK9
Targeted Patients: Hypercholesteremic patients unresponsive to statins - many will be FH pts heterozygous for mutant LDLR

Drug/Target: PF-04991532 Liver Glucokinase
Targeted Patients: Type 2 diabetes patients who are contra-indicated for or non-tolerant of metformin

Drug/Target: ATR-107/IL-21R
Targeted Patients: Patients with autoimmunes diseases that over-express IL-21

Drug/Target: Inotuzumab/CD-22
Targeted Patients: CD-22+ Hematological malignancies